Univercells receives $54m financing to advance bioprocessing platform


Gamma Biosciences has provided the investment to support continued expansion into the fast-growing gene therapy segment, specifically viral manufacturing

Photo as seen on Univercells company video showing the NevoLine platform

Univercells, a bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to €50 million ($54.09m) financing from new investment platform Gamma Biosciences.

The investment will be deployed in a newly created subsidiary of Univercells focused on accelerating the industrialisation and commercialisation of Univercells’ manufacturing technologies, including the NevoLine biomanufacturing platform and the scale-X bioreactor portfolio.

With the new financing, Univercells will focus on scaling the NevoLine platform and the scale-X portfolio with a comprehensive approach to streamline production, fund innovation, enable new product and application development and drive commercial acceleration.

Specifically, the investment is intended to support continued expansion into the fast-growing gene therapy segment, including new developments that will enable a range of best-in-class solutions for viral manufacturing.

Hugues Bultot, CEO of Univercells, said: “This investment builds on existing grants from the Bill & Melinda Gates Foundation, Global Health Investment Fund and European Investment Bank and secures our ability to create value for the market with speed, efficacy and reliability.”

Both the scale-X bioreactor portfolio and the NevoLine biomanufacturing platform have been designed and commercially validated to dramatically reduce the footprint, capital and operational expenditures required to produce a variety of biologic and viral products.

Sign up for your free email newsletter

The transaction is expected to close in the first half of 2020. Once the transaction is complete, Univercells’ remaining business will concentrate on developing a portfolio of vaccines and biosimilars to be delivered at an affordable price and establishing its services offering.